🔗 Share this article

While America undertakes unprecedented changes to its vaccine schedules, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by questioning Covid vaccines during the pandemic and has focused upon potential deaths following Covid immunization in her brief time at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Immunization Schedule

Agency leaders were set to unveil radical changes to the pediatric immunization program in December, aligning the US with the Danish immunization schedule, sources say – a substantial departure that would place the US at odds with a large portion of the international standard with no evidence for public health gain. The planned update has been pushed back until the new year.

Rather than the director of the vaccine center, Dr. Høeg is set to speak at the gathering. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to run the center this year.

A Shift at the FDA

This interim role may indicate a closer partnership between the pharmaceutical and biologics centers as Høeg and Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon reevaluating long-standing vaccines at the FDA.

Høeg has repeatedly called for halting some pediatric shot schedules in the US so as to align more like Denmark's approach, a nation with comprehensive healthcare and a number of inhabitants roughly the size of the state of Wisconsin.

In her initial statements, she has kept her attention on vaccines – traditionally the responsibility of Dr. Prasad, head of the FDA’s CBER – rather than medication approval.

Doubts Over Expertise

The appointee has little discernible experience in drug development, approval processes or leadership, which has been standard for former heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She appears not to have the necessary background” for overseeing the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in leading a large organization. She lacks background in pharmaceutical oversight.”

Past commissioners of the center would “grasp legal statutes and the underlying principles of drug development”, noted a former acting FDA commissioner. “Frankly, she lacks the type of experience that previous people who ran CBER have had.”

This division has an immense portfolio at the FDA, Woodcock emphasized.

“Everybody just zeroes in on the innovative therapies, but the off-patent medication office approves numerous off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and so forth, and each of these need to be managed,” Dr. Woodcock said. “The area you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial administrative element to the job, which oversees over 5,000 staff members. “It’s a huge management job, if you do it right,” the former official concluded.

Agency Reaction and Disputed Programs

Regarding questions about Høeg’s credentials and whether this assignment indicates increased cooperation among agency officials on immunizations, a spokesperson responded that the “inquiries rely on incorrect premises”.

“This background aligns with the responsibilities of her role,” the representative stated, pointing to the period Dr. Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the commissioner’s new expedited review system, a controversial rapid drug-approval program that allegedly troubled her predecessors. “How are these drugs being chosen for this voucher program? Who is making the choices?” Howard asked. “There is a lot of secrecy occurring at the regulatory body right now.”

Overall, he stated, “the agency looks to be trending towards less stringent rules of most medications, aside from vaccines.”

Established Past Work on Vaccines

With immunizations, Dr. Høeg has a more established, if troubling, track record, Howard have noted. She authored a analysis using unverified crowd-sourced reports to assess the frequency of myocarditis after Covid vaccination. She advised the Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccines are riskier than they are.

Part of her “desired changes” for the incoming government encompassed altering regulations for novel immunizations and ending “optional” immunizations, she remarked following the vote on a audio program. At the agency, Dr. Høeg has according to sources proposed barring adolescent males from getting COVID-19 vaccinations.

“She is an complete dogmatist who starts off with her beliefs and reverse-engineers to accommodate the data in a very deceptive, dishonest way,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Høeg became part of other skeptics, {like|